Evolve Private Wealth LLC Buys Shares of 65,754 Emergent Biosolutions Inc. $EBS

Evolve Private Wealth LLC purchased a new stake in Emergent Biosolutions Inc. (NYSE:EBS) during the first quarter, according to its most recent filing with the SEC. The firm purchased 65,754 shares of the biopharmaceutical company’s stock, valued at approximately $546,000.

Other large investors have also recently made changes to their positions in the company. Baron Wealth Management LLC raised its position in shares of Emergent Biosolutions by 40.2% in the 1st quarter. Baron Wealth Management LLC now owns 15,120 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 4,335 shares in the last quarter. Zacks Investment Management bought a new stake in Emergent Biosolutions during the fourth quarter valued at about $141,000. Millennium Management LLC boosted its position in Emergent Biosolutions by 205.4% during the fourth quarter. Millennium Management LLC now owns 237,674 shares of the biopharmaceutical company’s stock valued at $2,938,000 after purchasing an additional 159,850 shares in the last quarter. Aristeia Capital L.L.C. purchased a new position in Emergent Biosolutions in the fourth quarter valued at about $345,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in Emergent Biosolutions in the fourth quarter valued at about $283,000. 78.40% of the stock is owned by institutional investors.

Emergent Biosolutions Trading Down 5.7%

Emergent Biosolutions stock opened at $7.95 on Friday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.08 and a current ratio of 4.29. The stock has a market cap of $410.37 million, a PE ratio of -28.40 and a beta of 2.33. The stock has a 50-day moving average of $8.37 and a two-hundred day moving average of $9.76. Emergent Biosolutions Inc. has a one year low of $5.61 and a one year high of $14.06.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.46. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.The business had revenue of $156.10 million for the quarter, compared to analyst estimates of $145.00 million.

Insider Activity at Emergent Biosolutions

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 17,202 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $8.40, for a total transaction of $144,496.80. Following the sale, the director owned 79,941 shares of the company’s stock, valued at approximately $671,504.40. The trade was a 17.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Katkin sold 15,481 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $8.28, for a total transaction of $128,182.68. Following the transaction, the director owned 96,294 shares in the company, valued at $797,314.32. The trade was a 13.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 61,925 shares of company stock valued at $518,312 over the last 90 days. Company insiders own 6.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on EBS. Weiss Ratings lowered shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Wall Street Zen downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. HC Wainwright reduced their price objective on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Benchmark reiterated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Finally, UBS Group reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $12.00.

Emergent Biosolutions Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.